Categories: News

Alignment Healthcare to Participate in Two Upcoming Investor Conferences

ORANGE, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) — Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (Nasdaq: ALHC), a tech-enabled Medicare Advantage company, today announced that John Kao, founder and CEO, and Thomas Freeman, chief financial officer, will participate in the following upcoming investor conferences:

  • Cowen’s 42nd Annual Health Care Conference, being held virtually, including a fireside chat presentation on Tuesday, March 8, 2022, at 1:30 p.m. EST
  • Raymond James 43rd Annual Institutional Investor Conference, being held in Orlando, Florida, including a fireside chat presentation on Wednesday, March 9, 2022, at 11:35 a.m. EST. The webcast link will be available at https://ir.alignmenthealthcare.com/.

About Alignment Healthcare
Alignment Healthcare is a consumer-centric platform delivering customized health care in the United States to seniors and those who need it most, the chronically ill and frail, through its Medicare Advantage plans. The company provides partners and patients with customized care and service where they need it and when they need it, including clinical coordination, risk management and technology facilitation. Alignment Healthcare offers health plan options through Alignment Health Plan and also partners with select health plans to help deliver better benefits at lower costs.

Investor Contact
Bob East
ICR Westwicke for Alignment Healthcare
AlignmentIR@westwicke.com

Media Contact
Maggie Habib
mPR, Inc. for Alignment Healthcare
alignment@mpublicrelations.com 

Staff

Recent Posts

Is The DEA in Systemic Collapse: Corruption, Constitutional Violations, and a Seven-Year War Against Marijuana Medical Science

The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…

11 hours ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…

11 hours ago

Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting

Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…

11 hours ago